TrialAmerican journal of respiratory and critical care medicine2026

Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE).

Geoffrey Chupp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.